Challenges in the management of malignant hyperthermia in Colombia: Case report

Camila Andrea Lara Rosero; Wendy Cleves Ruiz; Lizeth Alexandra Chavarro Aguilar

doi:10.5554/22562087.e1152

Camila Andrea Lara Rosero Anesthesiology, Clínica Palermo. Bogotá, Colombia. https://orcid.org/0000-0002-3565-0252
Wendy Cleves Ruiz Anesthesiology, Clínica Palermo. Bogotá, Colombia. https://orcid.org/0000-0003-4994-7097
Lizeth Alexandra Chavarro Aguilar General Medicine, Universidad de La Sabana. Chía, Colombia. https://orcid.org/0009-0005-2554-6741

DOI: https://doi.org/10.5554/22562087.e1152

Keywords: Case report, Hyperthermia, Anesthetics, Calcium channels, Bronchospasm

Abstract References How to Cite Downloads

Abstract

Malignant hyperthermia is a potentially life-threatening pharmacogenetic disorder characterized by a hypermetabolic response triggered by exposure to halogenated anesthetics, succinylcholine, and other agents. This is a case of a 40-year-old woman who developed masseter muscle spasm, bronchospasm, hypercapnia, muscle stiffness, and hyperthermia upon the administration of general anesthesia at a clinic in the capital of Colombia. This resulted in a high clinical suspicion of malignant hyperthermia and hence the institutional protocol for management of this condition was activated. It should be highlighted however that the drug used to treat this condition—dantrolene—is not readily available at most clinical institutions in Colombia and in this case a special emergency line must be used in order for the drug to be delivered. Once the drug was received and administered, the patient experienced clinical and hemodynamic recovery, with satisfactory postoperative response. She was discharged on day five without any sequelae. This case report reviews the pathophysiology, diagnosis, and treatment for malignant hyperthermia, as well as the challenges in accessing pharmacological treatment in Colombia.

References

1. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93. https://doi.org/10.1186/s13023-015-0310-1.

2. Harrison GG, Isaacs H. Malignant hyperthermia. Anaesthesia. 1992;47:54-6. https://doi.org/10.1111/j.1365-2044.1992.tb01956.x.

3. Marilyn G, Barbara W, Gregory C, Gerald A, Erik B. Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology. 2008;108:603-11. https://doi.org/10.1097/ALN.0b013e318167aee2.

4. Gong X. Malignant hyperthermia when dantrolene is not readily available. BMC Anestesiol. 2021;119. https://doi.org/10.1186/s12871-021-01328-3.

5. Hopkins P. Malignant hyperthermia: pharmacology of triggering. BJA. 2011;104(1):48-56. https://doi.org/10.1093/bja/aer132.

6. Neira V. Hipertermia maligna en Bogotá. Colombian Journal of Anesthesiology. 1993;21:385-98. https://pesquisa.bvsalud.org/portal/resource/pt/lil-236817.

7. Castañeda A, Villaveces M, Ortiz C. Identification and successful timely treatment of malignant hyperthermia. Rev Chil Anest. 2023;52(4):422-5. https://doi.org/10.25237/revchilanestv52n04-17.

8. Lan H, Duan G, Zuo Y, Lou T, Xu J, Shao C, Wu J. Malignant hyperthermia: Report on a successful rescue of a case with the highest temperature of 44.2°C. Open Med. 2023;18(1):20230808. https://doi.org/10.1515/med-2023-0808.

9. Ndikontar R, Etoundi P, Tochie J, Bengono R, Minkande J. Malignant hyperthermia, a rare perioperative complication: case series and literature review. Oxford Med Case Rep. 2020;11. https://doi.org/10.1093/omcr/omaa101.

10. Sheila R, Natalia K, Philip M. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept. Anesthesiology. 2018;128:168-80. https://doi.org/10.1097/ALN.0000000000001878.

11. Larach M, Gronert G, Allen G, Brandom B, Lehman E. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010;110(2):498-507. https://doi.org/10.1213/ANE.0b013e3181c6b9b2.

12. Marilyn G, Russell L, Gregory C, Michael A, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology. 1994;80:771-9. https://doi.org/10.1097/00000542-199404000-00008.

13. McKenney K, Holman S. Delayed postoperative rhabdomyolysis in a patient subsequently diagnosed as malignant hyperthermia susceptible. Anesthesiology. 2002;96(3):764-5. https://doi.org/10.1097/00000542-200203000-00038.

14. Rüffert H, Bastian B, Bendixen D, Girard T, et al. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021;126(1):120-30. https://doi.org/10.1016/j.bja.2020.09.029

15. Hopkins P, Girard T, Dalay S, Jenkins B, et al. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anesthesia. 2021;76:655-64. https://doi.org/10.1111/anae.15317.

16. Schneiderbanger D, Johannsen S, Roewer N, Schuster F. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag. 2014;10:355-62. https://doi.org/10.2147/TCRM.S47632.

17. Riazi S, Kraeva N, Hopkins P. Updated guide for the management of malignant hyperthermia. Can J Anesth/J Can Anesth. 2018;65:709-21. https://doi.org/10.1007/s12630-018-1108-0.

18. Rincón-Valenzuela D, Gómez-Ardila C. Cost-benefit relationship of keeping dantrolene stocks from the point of view of healthcare institutions. Colombian Journal of Anesthesiology. 2020;48(2):63-70. https://doi.org/10.1097/CJ9.0000000000000147

19. Berrio Valencia MI, Ibarra C. Malignant hyperthermia: what we may need to have at hand. Colombian Journal of Anesthesiology. 2021;49(4). https://doi.org/10.5554/22562087.e993.

20. Calvache J. Economic analysis in anesthesiology in Colombia. Colombian Journal of Anesthesiology. 2020;48(2):61-2. https://doi.org/10.1097/CJ9.0000000000000154.

21. Gobernación de Antioquia. Protocolos y recursos para el tratamiento de pacientes que presentes hipertermia maligna en el Departamento de Antioquia. 2019. https://www.dssa.gov.co/index.php/emblematizacion/item/898-procedimiento-de-atencion-de-la-hipertermia-maligna-en-el-departamento-de-antioquia

22. Baquero N, Murillo A. Propuesta para el manejo de la hipertermia maligna en la red integrada de servicios de salud. Bogotá: Secretaría Distrital de Salud; 2018. https://www.saludcapital.gov.co/Documents/Hipertermia_Maligna.pdf&ved=2ahUKEwio8ff50t6JAxWbLlkFHZDDFsUQFnoECCAQAQ&usg=AOvVaw2cTTreQIPQkXv5efL8cuQt

How to Cite

1.

Lara Rosero CA, Cleves Ruiz W, Chavarro Aguilar LA. Challenges in the management of malignant hyperthermia in Colombia: Case report. Colomb. J. Anesthesiol. [Internet]. 2025 May 29 [cited 2026 Jan. 19];53(3). Available from: https://www.revcolanest.com.co/index.php/rca/article/view/1152